Concomitant Therapy Sample Clauses

Concomitant Therapy. This study is a comparison of standard care plus levosimendan to standard care plus placebo for the treatment of subjects in the immediate perioperative period. All patients should receive standard evidenced based therapies as recommended in local clinical practice guidelines. The patient’s regular per oral concomitant treatments (diuretics, digitalis, ACE inhibitors, nitrates, beta-blockers, and other medications e.g. antibiotics and analgesics) can be administered according to the investigator’s clinical judgment, All subjects may receive additional standard of care medications including inotropes, pressors, vasopressin, antiarrhythmics, diuretics, nitrates, and nitric oxide as needed. Due to the potentially hypotensive effects of the study drug, the concomitant use of vasodilatory active drugs should be used with caution as per the following guidance. Concomitant administration of nesiritide is not permitted; levosimendan should not be initiated within an hour of discontinuing nesiritide therapy.
AutoNDA by SimpleDocs
Concomitant Therapy. Concomitant medications will be summarized for the safety population.
Concomitant Therapy. The use of any concomitant medication, prescription or over-the-counter, is to be recorded on the subject’s electronic case report form (eCRF) at each visit, along with the reason the medication is taken, the dates of administration, and the dose.
Concomitant Therapy. 6.3.1 Cyclosporin A CsA can be continued, if already administered prior to screening. CsA can be withdrawn at any time, upon the judgement of the Investigator. CsA is not to be introduced de novo during the course of the study, once NI-0501 administration has started. As it is recommended in other HLH protocols, CsA concentrations should be monitored at least weekly to maintain trough levels of 150-200 ng/ml.
Concomitant Therapy. Throughout the study, investigators may prescribe any concomitant medications or treatments deemed necessary to provide adequate supportive care except for those listed in Section 6.9. Any medication including over the counter or prescription medicines, vitamins and/or herbal supplements that the participant is receiving at the time of enrollment / randomization or receives during the study through to week 24 must be recorded in the eCRF along with reason for use, dates of administration (including start and end dates) and dosage information (e.g. dose).
Concomitant Therapy. Patients enrolled in this trial may receive any conventional stroke treatment at the discretion of their attending physicians. Patients may not be enrolled in another therapeutic clinical trial until after exit from FAST-MAG after the 90 day visit. Patients may not be treated with other experimental stroke therapies. Treatment with tissue plasminogen activator within 3 hours of symptom onset, after exclusion of intracranial hemorrhage, is encouraged in patients who meet thrombolytic treatment criteria outlined in national consensus guidelines. Since in vitro compatibility has not been tested, a separate IV line should be employed if tissue plasminogen activator and the FAST- MAG trial solution are being infused simultaneously. Prespecified secondary analyses will examine the effect of study treatment in ischemic stroke patients treated with and treated without thrombolytic therapy. Evidence for the safety of concomitant magnesium sulfate and fibrinolytic therapy comes from the absence of adverse interaction among more than 41,000 MI patients receiving both magnesium sulfate and fibrinolytic agents in large cardiac trials, as reviewed above. [1,2] Additionally, the US manufacturer of TPA has on file no reports of adverse interactions between magnesium sulfate and tissue plasminogen activator in preclinical or clinical datasets (personal communication, Xxxxxxx Xxxxx, M.D, Genentech, 9/02) and the FDA Medwatch program has not logged any reports of adverse magnesium-TPA interactions (FDA FOIA inquiry, 9/02).
Concomitant Therapy. Concomitant medications are any prescription or over-the-counter preparations used by subjects during participation in the trial. Use of concomitant medications will be recorded on the Concomitant Medications case report form (CRF) beginning at the Screening Visit until the Week 16/Early Termination visit. The dose and dosing regimen of all prescription and non-prescription therapies and medications, including herbs, vitamins, or other nutritional supplements administered will be documented. Standardized home therapy program including Achilles tendon and plantar fascia stretching exercises and night splints will also be recorded throughout the study.
AutoNDA by SimpleDocs

Related to Concomitant Therapy

  • Information Systems Acquisition Development and Maintenance Security of System Files. To protect City Information Processing Systems and system files containing information, Service Provider will ensure that access to source code is restricted to authorized users whose specific job function necessitates such access.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Formation; Composition Within […***…] days after the Effective Date, the Parties shall establish a committee to oversee Development of Licensed Product(s) in the Territory in accordance with the Development Plan(s) for the same and to coordinate the Development activities of the Parties, and review and discuss the Development and Manufacture of Licensed Compound and Licensed Products (the “JDC”). Each Party shall initially appoint three (3) representatives to the JDC, with each representative having knowledge and expertise in the development of compounds and products similar to the Licensed Products and having sufficient seniority within the applicable Party to make decisions arising within the scope of the JDC’s responsibilities. The JDC may change its size from time to time if agreed by consensus among its members, provided that the JDC shall consist at all times of an equal number of representatives of each of Galapagos and Gilead. Each Party may replace its JDC representatives at any time upon written notice to the other Party. The JDC may invite non-members to participate in the discussions and meetings of the JDC, provided that such participants shall have no voting authority at the JDC. The JDC shall have a chairperson, who shall serve for a term of one (1) year, and who shall be selected alternately, on an annual basis, by Galapagos or Gilead. The initial chairperson shall be selected by […***…]. The role of the chairperson shall be to convene and preside at meetings of the JDC and to ensure the preparation of minutes, but the chairperson shall have no additional powers or rights beyond those held by the other JDC representatives.

  • Medical Services We do not Cover medical services or dental services that are medical in nature, including any Hospital charges or prescription drug charges.

  • Disaster Recovery and Business Continuity The Parties shall comply with the provisions of Schedule 5 (Disaster Recovery and Business Continuity).

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development 3.3 Within twenty (20) Working Days after the Commencement Date and in accordance with paragraphs 3.10 to 3.12 (Amendment and Revision), the Contractor will prepare and deliver to the Authority for approval the full and final Security Plan which will be based on the draft Security Plan set out in Appendix B.

  • Technical Services Party B will provide technical services and training to Party A, taking advantage of Party B’s advanced network, website and multimedia technologies to improve Party A’s system integration. Such technical services shall include:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!